Drägerwerk reports weaker third-quarter EBIT. Drägerwerk stock gains 1.04 percent

Published on 10/16/2026 at 10:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Drägerwerk kept its 2026 outlook after EBIT fell to EUR 48.00 million. Drägerwerk stock costs EUR 97.30 on October 16, 2026, 1.04 percent above Xetra close.

Quarterly pressure and analyst view

On October 14, 2026, preliminary EBIT reached EUR 48.00 million versus EUR 56.70 million a year earlier.
MWB Research kept its EUR 135.00 target on October 15, 2026.
Drägerwerk stock trades at EUR 97.30 at 10:30 a.m. CEST at Lang & Schwarz on October 16, 2026, 1.04 percent above the Xetra close of October 15, 2026.

Bauhaus-Konstruktivismus-Poster mit MEDIZINTECHNIK-Schriftzug und geometrischen Primärfarben — Drägerwerk AG & Co. KGaA Bauhaus-Poster Medizintechnik geometrische Formen Primärfarben Konstruktivismus DE0005550636, Illustration mit AI erstellt.

Drägerwerk stock (ISIN DE0005550636) was trading at EUR 97.30 at Lang & Schwarz on October 16, 2026, at 10:30 a.m. CEST, up 1.04 percent versus the Xetra close of October 15, 2026 at EUR 96.30. The medical and safety technology group had reported weaker preliminary third-quarter operating earnings on October 14, 2026, while keeping its full-year outlook.

Quarterly EBIT shows cost pressure

According to Deutsche Boerse, Drägerwerk generated preliminary third-quarter EBIT of EUR 48.00 million, down from EUR 56.70 million in the third quarter of 2025. The result included EUR 20.10 million in tariff refunds, while the EBIT margin declined to 5.60 percent from 6.80 percent.

Revenue still increased to EUR 851.00 million from EUR 833.30 million in the third quarter of 2025. The contrast is important for investors: sales rose 2.10 percent nominally, but higher functional costs weighed on operating profitability.

What does order growth mean?

Order intake rose 8.20 percent nominally to EUR 926.00 million in the third quarter of 2026. Safety Technology led the improvement with order intake of EUR 452.00 million, up 21.70 percent, while Medical Technology order intake fell 2.20 percent to EUR 474.00 million, according to Deutsche Boerse. For the first nine months of 2026, EBIT reached EUR 112.00 million versus EUR 77.10 million a year earlier, although EUR 27.90 million of tariff refunds contributed to the result.

Drägerwerk confirmed 2026 revenue growth of 2.00 to 6.00 percent excluding currency effects and an EBIT margin of 6.00 to 8.00 percent. The company will publish its full quarterly statement on October 29, 2026, according to Deutsche Boerse.

Analyst target stays at EUR 135.00

MWB Research kept its Buy rating and EUR 135.00 price target on October 15, 2026, while lowering its 2026 earnings estimates after the weak third quarter, as reported by Finanznachrichten. The same analysis identifies November 18, 2026 as the date of Drägerwerk's Capital Markets Day.

Stock holds above the Xetra close

The current market picture combines a 1.04 percent intraday gain with a clear earnings test ahead. Drägerwerk stock was trading at EUR 97.30 at Lang & Schwarz on October 16, 2026, at 10:30 a.m. CEST, or EUR 1.00 above the Xetra close of October 15, 2026 at EUR 96.30.

The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.